GS Global expands its portfolio with DEXLEVO for the EU and North America market
22.6.2022 14:21:00 EEST | Business Wire | Press release
GS, which has announced its expansion into the bio business by acquiring Hugel, a botulinum toxin manufacturer, now seeks further business expansion. The group plans to diversify its business portfolio by collaborating with technology-competitive bio ventures. Recently, it is seen to consider synergy by combining botulinum toxin and fillers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005613/en/
(Graphic: Business Wire)
According to industry sources, GS’s trading arm GS Global is exploring the global filler market by signing a strategic partnership with DEXLEVO on May 20. The agreement worth 10 million dollars (KRW 12.7 billion) aims to distribute GOURI, a liquid PCL injectable of DEXLEVO in Turkey. GS is also eyeing penetrating markets in Europe and the Greater China Region.
GS focuses on DEXLEVO’s superior technology which can generate synergy with its bio portfolio. GOURI is the world’s first filler based on polycaprolactone (PCL), a biodegradable solubilized polymer. The product evenly spreads to human faces without particles after injection to form collagen.
Furthermore, the group noted the fact that filler and botulinum are complementary goods under the same aesthetic portfolio. DEXLEVO’s product GOURI received CE certification in May 2021, paving the way for exports. GS intends to export Hugel’s botulinum toxin utilizing the distribution network for DEXLEVO’s filler.
Industry officials said that Hugel had built a relationship with DEXLEVO by securing the right to exclusive distribution of DEXLEVO’s liquid polymer fillers in Korea before it was acquired by GS, and thus GS is expecting synergy when it expands the botulinum toxin business.
GS has made various moves to expand its bio business. Last year GS Global signed a business agreement with AT Sens, a developer of ECG (electrocardiogram) monitors to explore the North American market. The agreement was to sell AT-Patch, the first long-term uninterrupted ambulatory cardiac monitor launched in Korea by AT Sens to North America.
In addition, the Future Business Team of the holding company GS is exploring new businesses to seek additional sources of growth through M&A. Future business Team consists of team leader Hur Seo-Hong, and Executive Directors Gwak Won Cheol, Hwang Jae-eung, and Gu Ja-yong. The team includes more executives and most of them are looking for additional investment in biotech.
A GS group official said, "Collaboration with DEXLEVO is one of our multiple strategies to secure sources of future growth, and we will continuously explore new businesses in various areas including the bio sector."
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005613/en/
Contact information
DEXLEVO
Chris Jeong
chrisjeong@dexelvo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KILL Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 05:14:00 EEST | Press release
Samsung Bioepis Co., Ltd. requests that their press release NewsItemId: 20260505353718 “Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)” be killed. The release was issued prematurely by Samsung Bioepis Co., Ltd. The news release will be updated and redistributed in the near future, incorporating further information on SB27.
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 02:00:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sourced Keytruda every 3 weeks, maximum 18 cycles over about 51 weeks, and blood samples were collected. The preliminary pharmacokinetic evaluation indicates t
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 01:00:00 EEST | Press release
Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing significant latency and complexity. Megaport DDoS Protection removes these challenges by integrating fabric-native protection directl
IFF Reports First Quarter 2026 Results5.5.2026 23:23:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, w
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 23:06:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in US dollars and 3 percent in constant currency compared to Q4 of the prior yea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom